Abnova Taiwan Corp (4133) - Total Liabilities
Based on the latest financial reports, Abnova Taiwan Corp (4133) has total liabilities worth NT$70.74 Million TWD (≈ $2.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abnova Taiwan Corp - Total Liabilities Trend (2008–2025)
This chart illustrates how Abnova Taiwan Corp's total liabilities have evolved over time, based on quarterly financial data. See Abnova Taiwan Corp short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Abnova Taiwan Corp Competitors by Total Liabilities
The table below lists competitors of Abnova Taiwan Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Insung Information Co. Ltd
KQ:033230
|
Korea | ₩114.03 Billion |
|
BG Staffing Inc
NYSE:BGSF
|
USA | $32.89 Million |
|
BJC Heavy Industries Public Company Limited
BK:BJCHI
|
Thailand | ฿274.97 Million |
|
Matahari Putra Prima Tbk
JK:MPPA
|
Indonesia | Rp3.12 Trillion |
|
FOODWELL Co. Ltd
KQ:005670
|
Korea | ₩131.62 Billion |
|
Globetronics Tech Bhd
KLSE:7022
|
Malaysia | RM24.27 Million |
|
ALANDEQGRP FPO
AU:AEG
|
Australia | AU$3.09 Million |
|
Phunware Inc
NASDAQ:PHUN
|
USA | $6.49 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Abnova Taiwan Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4133 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abnova Taiwan Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abnova Taiwan Corp (2008–2025)
The table below shows the annual total liabilities of Abnova Taiwan Corp from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$70.74 Million ≈ $2.23 Million |
-22.81% |
| 2024-12-31 | NT$91.65 Million ≈ $2.89 Million |
+32.01% |
| 2023-12-31 | NT$69.42 Million ≈ $2.19 Million |
-16.19% |
| 2022-12-31 | NT$82.83 Million ≈ $2.61 Million |
+16.19% |
| 2021-12-31 | NT$71.29 Million ≈ $2.25 Million |
-14.61% |
| 2020-12-31 | NT$83.49 Million ≈ $2.63 Million |
+16.63% |
| 2019-12-31 | NT$71.59 Million ≈ $2.26 Million |
+5.64% |
| 2018-12-31 | NT$67.77 Million ≈ $2.14 Million |
-14.28% |
| 2017-12-31 | NT$79.05 Million ≈ $2.49 Million |
+9.71% |
| 2016-12-31 | NT$72.06 Million ≈ $2.27 Million |
-12.50% |
| 2015-12-31 | NT$82.35 Million ≈ $2.59 Million |
+5.37% |
| 2014-12-31 | NT$78.15 Million ≈ $2.46 Million |
+41.02% |
| 2013-12-31 | NT$55.42 Million ≈ $1.75 Million |
-12.20% |
| 2012-12-31 | NT$63.12 Million ≈ $1.99 Million |
-25.31% |
| 2011-12-31 | NT$84.51 Million ≈ $2.66 Million |
+31.55% |
| 2010-12-31 | NT$64.24 Million ≈ $2.02 Million |
-32.62% |
| 2009-12-31 | NT$95.34 Million ≈ $3.00 Million |
-15.41% |
| 2008-12-31 | NT$112.71 Million ≈ $3.55 Million |
-- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more